R Krumbach, J Schüler, M Hofmann… - European Journal of …, 2011 - Elsevier Cetuximab (Erbitux®) targets the epidermal growth factor receptor (EGFR) and is approved for treatment of colorectal and head and neck cancer. Despite wide expression of EGFR, only a subgroup of cancer patients responds to cetuximab therapy. In the present study we ... Cited by 1 - Related articles - All 3 versions
RM de Medeiros, DM Junqueira… - Journal of Medical …, 2011 - Wiley Online Library In Southernmost Brazil HIV-1 subtypes B, C, and CRF31_BC co-circulates and, since 1996 with the implementation of free access to highly active antiretroviral treatment (HAART), this epidemic is under a quite characteristic selective pressure. The profile of mutations and ...
[HTML] from plos.orgT Qin, R Castoro, S El Ahdab, J Jelinek, X Wang… - PloS one, 2011 - dx.plos.org ... Most genes showed no differences by response, but the CDA/DCK ratio was 3 fold higher in non-responders than responders (P<.05), suggesting that this could be a mechanism of primary resistance. ... DAC metabolism gene expression in primaryresistance. ... Cached
[PDF] from krakow.plM Zwoliñska-Wcis³o… - Pharmacological Reports, 2011 - if-pan.krakow.pl Department of Pharmaceutical Microbiology of the Jagiellonian University Medical College, Medyczna 9, PL 30-688 Kraków, Poland ... Gastroenterological Outpatient Clinic „Falck Medycyna”, Kraków, Poland ! Chair of Gastroenterology Hepatology and Infections Diseases, ... View as HTML
M Tiseo, F Gelsomino, D Boggiani, B Bortesi… - Lung Cancer, 2011 - Elsevier ... of acquired resistance have been identified, a secondary T790M mutation in EGFR exon 20 and the amplification of the MET gene [2]. Furthermore, 20–30% of EGFR mutated patients do not respond to EGFR-TKIs due to unknown mechanisms of primaryresistance. ... Cited by 3 - Related articles - All 3 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
